Skip to content
ppharmaranks
Menu

CD20-directed Cytolytic Antibody drugs compared

Compare all 1 CD20-directed Cytolytic Antibody drug side by side, used for conditions such as arthritis, rheumatoid, leukemia, lymphoid, granulomatosis with polyangiitis. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores.

Full ranking · 1 drugs

  1. 1

    rituxan

    Rituximab

    70/100

Frequently asked questions

What is the CD20-directed Cytolytic Antibody drug class?

CD20-directed Cytolytic Antibody is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 1 CD20-directed Cytolytic Antibody product, each independently rated.

Are all CD20-directed Cytolytic Antibody drugs the same?

No. CD20-directed Cytolytic Antibody drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

What conditions do CD20-directed Cytolytic Antibody drugs treat?

Per NIH RxClass drug-classification data, CD20-directed Cytolytic Antibody drugs are used for conditions including arthritis, rheumatoid, leukemia, lymphoid, granulomatosis with polyangiitis, lymphoma, b-cell, lymphoma, mantle-cell, microscopic polyangiitis.

Sources: the CD20-directed Cytolytic Antibody class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class). Ratings are pharmaranks’ independent FDA recall-safety analysis.